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Background: People who inject drugs (PWID) are at highest risk for hepatitis C virus (HCV) infection, yet many
remain unaware of their infection status. New anti-HCV rapid testing has high potential to impact this.
Methods: Young adult (<30 years) active PWID were offered either the rapid OraQuick® or standard anti-HCV test
involving phlebotomy, then asked to complete a short questionnaire about testing perceptions and preferences.
Sample characteristics, service utilization, and injection risk exposures are assessed with the HCV testing choice as
the outcome, testing preferences, and reasons for preference.
Results: Of 129 participants: 82.9% (n = 107) chose the rapid test. There were no significant differences between
those who chose rapid vs. standard testing. A majority (60.2%) chose the rapid test for quick results; most (60.9%)
felt the rapid test was accurate, and less painful (53.3%) than the tests involving venipuncture.
Conclusions: OraQuick® anti-HCV rapid test was widely accepted among young PWID. Our results substantiate the
valuable potential of anti-HCV rapid testing for HCV screening in this high risk population.
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Hepatitis C virus (HCV) remains a serious public health
problem [1]. In the US, National Health and Nutrition
Examination Surveys (NHANES) data estimate 2.2-3.2
million people in the U.S. are living with HCV, which is
likely an underestimate [2]. Previous analysis has esti-
mated that NHANES does not account for an additional
1.1 million infected persons [3,4]. HCV is a significant
cause of liver disease, cirrhosis, and liver cancer [5,6], and
now surpasses HIV as a cause of death [7]. Injection drug
use is the leading behavioral risk factor for HCV infection
[2,8] and 75%-90% of long-term people who inject drugs
(PWID) are reported to be anti-HCV positive [9].
Despite overall declining incidence of HCV infection
in the US since 1992 [8], recent outbreaks of HCV have
been documented among young adult PWID [10-13].
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unless otherwise stated.opiate misuse among youth, which may confer higher
risks of HCV transmission [14,15]. Young PWID also
contend with the exceptional rates of seroconversion
associated with the first few years of initiating injection
drug use [16] and are often reliant upon social relationships
in which risk-related injection behaviors, including sharing
non-sterile injection equipment, are conducted [17,18].
The U.S. Centers for Disease Control and Prevention
and U.S. Prevention Services (CDC) Task Force recom-
mends routine anti-HCV testing for anyone who has
injected drugs and one-time testing for adults born
between 1945–1965 [19,20]. Testing for HCV may enhance
prevention efforts, improve efforts to identify people eligible
for treatment, and increase uptake into care [3,21-24].
Some studies suggest that PWID who know their serostatus
may reduce some high-risk injection-related behaviors
[25-27], however others have not observed this [22,24,28].
Young PWID may also engage in seroadaptive prac-
tices, based on their perception of their partners’ HCV
status [18,29], although others have not observed this
[22,24,28,30,31]. Finally, identifying HCV infections amongtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and treatment.
Many of those at risk for and living with HCV are
unaware of their serostatus [3,26]. One multi-city study
reported that as many as 72% of anti-HCV positive young
injectors did not know their status [25]. The low numbers
of PWID who test for HCV may be due in small or large
part to the requirements of standard testing algorithms,
which include at the least, an enzyme immunoassay (EIA)
followed by an HCV RNA test. These tests, which involve
phlebotomy and laboratory work, significant waiting times,
as well as potentially re-drawing of blood (for RNA con-
firmatory testing) are potential barriers to testing and
results disclosure for people, including PWID, who may
be homeless, lack access to health insurance, unable or
unwilling to return for results, or not have accessible veins
[21,32,33].
Treatment of HCV has been previously shown to be
feasible and just as effective among PWID as non-
injectors [34-37], yet many PWID have avoided treatment
due to fears of the adverse effects of the medications
and the difficulties of balancing life circumstances and
comorbidities, or have been restricted by physicians
who anticipate poor adherence [37]. Advances in HCV
treatment options improve side-effect profiles, potentially
shorten the course of treatment and increase rates of
sustained virologic response (SVR) [38]. These advances
may increase demand and access for care and treatment
among young adult PWID, who historically have had
little access to HCV treatment [39,40], as well as enhance
the incentive to know one’s HCV status, simultaneously
increasing the value of faster, easier and more accessible
testing options.
Rapid HIV testing has been demonstrated to be accept-
able among young, high-risk and traditionally hard-
to-reach populations and in community-based venues
[41-44] and has been associated with an increased test
and disclosure acceptance [43,45] and entering care [46].
Recently available anti-HCV rapid testing is similarly
accurate to conventional EIA testing [47,48] and has been
demonstrated to be appropriate in community settings
[21]. Comparisons between the HIV and HCV tests are
limited, however by the potentially different meanings of
each test (positive anti-HIV antibody is either a) positive
viral infection, or b) false positive, whereas a positive anti-
HCV test may indicate either a) positive viral infection, b)
past, resolved infection, or c) false positive). Despite these
differences, it seems reasonable to assume that similar
levels of preference and acceptability toward the rapid
HCV may also extrapolate to increased number of people
who test for HCV, know their HCV status and enter care.
To date, we know of no studies that analyze testing
preference and acceptability of anti-HCV rapid tests
against traditional phlebotomy-based blood draw testingamong young adult PWID. This study of participants of a
prospective observational cohort of young PWID measures
1) choice of either rapid testing finger prick or standard
laboratory-based testing via venipuncture and 2) levels of
preference and acceptability toward the rapid test based on
a short questionnaire. Preliminary results showed high
levels of preference and acceptability for the rapid test [49].
Methods
Study population data collection
The UFO Study is an ongoing prospective observational
study of HCV risk and incidence in young PWID; results
and methods have been described in detail elsewhere
[17,50]. For this sub-study, newly enrolled participants
who completed a baseline visit (Visit 1 of the prospect-
ive study) between June 2012 and August 2013 were
approached to complete the HCV rapid test acceptability
survey. Participants enrolled prior to June 2012 were
approached at a scheduled quarterly follow-up study visit.
Baseline visit eligibility criteria included subjects under
30 years of age, self-report having injected in the last
30 days at baseline, and self-report negative or unknown
HCV RNA status; prospective participants with unknown
HCV status, or anti-HCV positive but HCV RNA nega-
tive, were eligible to participate in the study. Baseline
and follow-up visits included both anti-HCV testing
and HCV RNA testing, as well as completion of an
interviewer-administered behavioral survey. Effective
June 2012, participants were offered a choice between anti-
HCV rapid testing (OraSure© Technologies: Bethlehem,
PA) and standard laboratory-based anti-HCV testing via
venipuncture beginning in June 2012. When study partici-
pants chose the rapid test method, results were available
and disclosed at that time, and one week later for those
who chose phlebotomy-based testing. Venipuncture for
HCV RNA testing was routine for these study visits
(for HCV viral RNA testing) as well as collection of
dried blood spot (DBS) [51], therefore all participants
underwent both phlebotomy and finger prick testing
regardless of test choice. HCV rapid test results were
disclosed prior to the administration of the HCV rapid
test survey. All participants received pre- and post-test
risk reduction counseling. Health care referrals were
provided for participants with HCV infection. The
protocol for this study was reviewed and approved by
the UCSF Human Research Protection Institutional
Review Board. Written informed consent was obtained
from all participants.
Data and specimen collection occurred at UCSF Clinical
Research Services’ Tenderloin Clinical Research Center
(TCRC), which has a Clinical Laboratory Improvement
Amendments (CLIA) waiver, a regulatory institution
overseeing laboratory testing of humans in the US that
waives certification for laboratories that perform simple
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(FDA) and Center for Disease Control and Prevention
(CDC). The research staff included trained phlebotomists,
interviewers, and counselors who had training and experi-
ence with HIV and HCV testing protocols and risk
reduction counseling with the PWID population.
Measures
Data collected from the behavioral survey, including: (a)
participant sociodemographic characteristics, (b) previous
HIV testing history and self-reported anti-HIV status, (c)
service utilization, including having used needle exchange
in the past 3 months; and (d) risk behaviors associated
with number of years injecting was assessed in association
with anti-HCV testing preference (rapid vs. standard).
The ‘rapid HCV test survey’ measured preferences, per-
ceptions and reasons for testing choice. This survey,
adapted from a previously published survey assessing
acceptability of rapid HIV testing [52], asked ‘which test
they took’, ‘which test they preferred’, ‘what is MAIN
reason for [testing preference]’. Additionally, we asked re-
search participants to provide reasons for said preferences
and about their perception of the accuracy of the ‘new’
rapid test using a series of 4-point Likert scale questions.
Statistical analysis
The principal outcome of interest was the choice of anti-
HCV test: rapid or standard. Frequencies and measures of
central tendency were used to describe sample character-
istics and perception of HCV rapid testing (preferences,
perceptions and reasons for testing choice). Fisher’s exact
test was used to describe the associations between base-
line characteristics and testing choice. Analyses were done
using STATA 13.0 (StataCorp, College Station, Texas).
Results
From June 2012 through August 2013, 129 participants
were recruited, 127 (98.4%) completed survey questions
about their point of care testing preference. A majority,
82.9% (n = 107) chose to receive the anti-HCV rapid test.
Table 1 describes testing choice by sample characteris-
tics. The overall median age of participants was 25.1 years.
More than half of participants were male (n = 88, 68.2%),
white (n = 74, 57.4%), previously tested for HIV (n = 105,
82%), were self-reported HIV negative (n = 101, 78.3%),
and were homeless (n = 101, 78.3). Most participants had
previously accessed needle exchange in the previous
3 months (n = 95, 73.6%). The median years injecting was
4.2 (1.7-7.5). Testing preference did not significantly differ
between any of the participant descriptors, HIV testing
history, self-reported HIV status, service utilization or
number of years injecting (Table 1).
Table 2 presents perceptions of the ‘rapid test’ among
the sample participants. Of those who chose the rapidtest, 98% (105/107) responded to the questionnaire, and
81.9% (n = 86) of those preferred the rapid test to the
phlebotomy-based standard test. More than half of par-
ticipants who chose the rapid test did so because they
wanted fast results (60.2%). Participants who chose the
rapid test also reported feeling that the rapid test was
just as or more accurate (62.3%), and the same or less
painful (86.8%) than the conventional blood draw test.
Most participants who received the rapid test agreed
that they preferred receiving their results the same day
(84.4%) and that they understood their results (97.5%).
The majority of these participants would recommend
the rapid test to a friend (93.9%). Very few participants
agreed that it would have been better to wait a week to
receive their results (3.1%). Perceptions of the rapid test
among rapid testers did not differ by anti-HCV result
(data not shown).
Of the 21 participants who opted for the standard HCV
test and completed the questionnaire, 38.1% (n = 8) chose
that test because they felt the test was older and more
trusted. This was the most common reason given for
choosing the standard test. Other participants stated
that they did not want their results that day (n = 3,
14.3%), feeling that the standard was a more convenient
test (n = 3, 14.3%), being afraid of fingers pricks (n = 2,
9.5%), and feeling that the standard test is less painful
(n = 1, 4.8%). Overall, 17 (13.2%) of all participants felt
that the rapid test was to some degree less accurate
than the standard test “less quality control”, (n = 4),
needs to be confirmed (n = 3), is too fast (n = 3), is too
new (n = 3), or uses less blood (n = 2).Discussion
This study demonstrates that the OraQuick® anti-HCV
rapid test by finger-prick is widely accepted and preferred
in this sample of young adult PWID in San Francisco. This
preference was not associated with sociodemographic char-
acteristics, including age, gender, race/ethnicity, HCV and
HIV testing history, or reported injection risk exposures.
The principal reason participants indicated for preferring
the rapid test was wanting fast results regarding anti-HCV
status and with potentially less pain than with testing using
a blood draw. An important indication that the test was
acceptable was the widespread endorsement that they
would recommend it to a friend. As hoped, these results
suggest that rapid HCV testing has potential to increase
HCV testing and knowledge of exposure to HCV infec-
tion. We also found that test preference did not differ by
anti-HCV results; those testing positive were equally likely
to favor the rapid test as those testing negative. This is
important since follow-up testing for those testing anti-
HCV positive will require a blood draw for HCV RNA
testing. These results suggest that those at highest risk
Table 1 Characteristics of UFO study participants
participating in the Rapid HCV testing study: (1) overall; and









N N (%) N (%)
Median age (range,
IQR)[yrs]
25 (23–27) 25 (23–27) 25 (23–27) 0.75
Gender
Male 88 72 (81.8) 16 (18.2) 0.80
Female 40 34 (85.0) 6 (15.0)
Ethnicity
Non-white 55 48 (87.3) 7 (12.7) 0.35
White 74 59 (79.7) 15 (20.3)
Ethnicity
Asian, Asian-American 1 1 (100) 0 (0) 0.56
African American 5 4 (80.0) 1 (20.0)
Filipino 1 1 (100) 0 (0)
Latino/Hispanic 7 6 (85.7) 1 (14.3)
Native American 5 3 (60.0) 2 (40.0)
Caucasian 74 59 (79.7) 15 (20.3)
Other 9 8 (88.9) 1 (11.1)
Mixed 27 25 (92.6) 2 (7.4)
Previously tested
for HIV
Yes 105 86 (81.9) 19 (18.1) 1.00




Negative 101 83 (82.2) 18 (17.8) 1.00
Positive 5 4 (80.0) 1 (20.0)
Homeless, last
3 months
Yes 101 82 (81.2) 19 (18.8) 0.40
No 28 25 (89.3) 3 (10.7)
Completed grade 12
Yes 93 78 (83.9) 15 (16.1) 0.79
No 36 29 (80.6) 7 (19.4)
Seen health provider,
last 3 months
Yes 64 52 (81.3) 12 (18.8) 0.82
No 64 54 (84.4) 10 (15.6)
Missing* 1 1
Table 1 Characteristics of UFO study participants
participating in the Rapid HCV testing study: (1) overall; and





Yes 95 77 (81.1) 18 (19) 0.43




4.2 (1.7-7.5) 4 (1.5-7.7) 4.9 (2.1-6.5) 0.51
Inject every day in
past 30 days
Yes 37 29 (78.4) 8 (21.6) 0.44
No 91 77 (84.6) 14 (15.4)
Missing* 1 1
*Missing values were not factored into the proportions or p-values presented.
1Fisher’s Exact Test for frequency and Kruskal-Wallis Test for median
value comparison.
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for additional testing that may follow positive results.
In the U.S., there is growing concern about an emer-
gent HCV epidemic in young adult PWID, not only in
urban, but suburban and rural areas [13], and reflected by
disproportionate increases in the number of acute HCV
cases identified among young PWID and reported to the
CDC in the past five years [8]. Our population is compar-
able to other studies of young adult PWID sampled in
urban areas and in national surveys [17,25,53-56]. The
large number of participants who were unstably housed
or homeless presents another significant concern and
potential opportunity for the implementation of this
test. Evidence shows worrying rates of injection drug
use among homeless youth [57]. These factors, and
others, including mobility [58], coupled with barriers
to phlebotomy-based testing faced by homeless youth
[21,32,33], increase the imperative for more accessible
options for HCV testing, prevention and linkages to
care, and reinforce our focus on this population.
This test offers a critical opportunity to increase HCV
testing among high risk young adult PWID, as well as
access to other health services, including counseling to
reduce risk behaviors and linkage to care. As evidenced
by the introduction of rapid HIV testing, being able
to offer rapid testing and immediate results may be
the determining factor in increasing testing numbers,
results disclosures and appropriate counseling services
[43,45,59]. Comprehensive prevention programs that
provide testing options, along with clean injection equip-
ment, substance use treatment options, health education,
and opportunities to access treatment and care, could
Table 2 Perceptions about HCV rapid test among young
people who inject drugs in the UFO Study
Variable N (%)
Among all participants (N = 129)
Belief in accuracy of rapid vs. Standard anti-HCV test
Much less accurate 3 (2.3)
Somewhat accurate 14 (10.9)
Just as accurate 70 (54.7)
More accurate 5 (3.9)
Much more accurate 3 (2.3)
Don’t know 33 (25.8)
Among HCV Rapid Test takers (N = 107)
Main reason for choosing rapid anti-HCV test: (n = 83)*
1. Wanted fast results 50 (60.2)
2. Rapid test is more convenient 10 (12.1)
3. I am afraid of needles or blood draws 1 (1.2)
4. I have bad veins 3 (3.6)
5. Rapid test is less painful 4 (4.8)
6. Rapid test requires less blood 6 (7.2)
7. Rapid test is less stressful 4 (4.8)
8. Rapid test is newer 1 (1.2)
9. I trust the research staff experience 2 (2.4)
10. I was concerned I wouldn’t get paid 2 (2.4)
Compared to standard blood draw, getting a finger
prick was: (n = 99)
Much more painful 4 (4.0)
More painful 9 (9.1)
About the same amount of pain 33 (33.3)
Less painful 29 (29.3)
Much less painful 24 (24.2)
‘I have tested for HCV in the past and I prefer receiving
my results the same day’ (n = 96)
Strongly agree 30 (31.3)
Agree 51 (53.1)
Disagree 13 (13.5)
Strongly disagree 2 (2.1)
‘It would have been better to wait a week’ (n = 97)
Strongly agree 0 (0)
Agree 3 (3.1)
Disagree 66 (68.0)
Strongly disagree 28 (28.9)
‘I understand the results of my test’ (n = 96)
Strongly agree 50 (52.1)
Agree 44 (45.8)
Disagree 1 (1)
Strongly disagree 1 (1)
Table 2 Perceptions about HCV rapid test among young
people who inject drugs in the UFO Study (Continued)
‘I would recommend rapid test to a friend’ (n = 98)
Strongly agree 42 (42.9)
Agree 50 (51)
Disagree 2 (2)
Strongly disagree 4 (4.1)
*Reasons for missing responses include interviewer error (n = 13) and a faulty
skip pattern (corrected early in data collection) in which participants who
preferred standard anti-HCV testing were not asked a follow-up question
regarding testing preference reason (n = 7).
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[60,61]. Rapid HCV testing could be an essential com-
ponent of such an inclusive approach. A majority (over
80%) of participants in this study report using needle
exchange services. Implementation of rapid testing at
such programs has potential to reach a large number of
PWID. Knowing one’s HCV status is also critical to seek-
ing and getting access to the appropriate care. Improved
treatment options that are more tolerable and effective are
likely to increase the demand for faster, more accessible
testing options, together hopefully increasing access to
care and treatment.
The rapid anti-HCV test remains limited by the need
for nuanced counseling messages associated with anti-
HCV testing, and by the need to confirm positive results.
A single rapid test does not distinguish between those
individuals with current HCV infection and those with
past infection who have cleared the virus, nor will it give a
clear picture of acute versus chronic infection. For this
reason, viral RNA testing remains necessary for accurate
knowledge of HCV infection status [5]. The HCV RNA
test is associated with phlebotomy and lab work and
participants must return for results, although use of
dried-blood spots for HCV RNA testing is feasible and
accurate [62,63] and testers might circumvent phlebotomy
in some cases. In addition, testing sites without trained
phlebotomists or the resources to offer RNA testing will
have to provide referrals to clinical sites for people with
positive HCV antibody. Many of the aforementioned bar-
riers associated with testing that young PWID face, such
as venipuncture and returning for results, thus remain a
potential problem if someone tests anti-HCV positive.
Although the antibody testing does not give a clear
picture of infection status or timeline, the rapid test may
be more accessible and cheaper, facilitating serial testing
among those who are negative and at high risk. Rapid
testing could, then, help providers estimate a window of
when someone newly acquires HCV, offering an important
opportunity for prevention messages and referral to con-
firmatory testing and care, as new infections are marked by
high viremia and these individuals are potentially at high
risk of HCV transmission [60].
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already engaged in a study of HCV transmission and
risk, had previously agreed to regular HCV testing, and
may have received a HCV test prior to the baseline visit.
Participants also understood that they would receive a
phlebotomy blood draw as part of that study, regardless
of whether they chose the rapid test or not. This study,
therefore, does not necessarily represent individuals
who are not already seeking and engaged in testing.
Nevertheless, our population is highly reflective of the
population at high risk of HCV, especially those in
urban areas [13,16,57]. Generalizability of the favorable
preference profile for the rapid test is also limited by
the fact that all participants underwent phlebotomy-based
testing for HCV RNA testing. Current HCV screening
algorithms recommend reflexive testing for HCV viremia
only among those testing anti-HCV positive [5]. Further-
more, as the rapid test may be implemented in settings
where there are limited clinical staff, options for HCV
RNA testing may be more limited. However, given the
high rate of infection and the long seronegative viremic
window observed in acute and early HCV infection,
there is a need to find other methods to detect viremia
in PWID in order to reduce the risk of HCV transmission
during the seronegative window [51]. It is possible that
our sample also had familiarity with rapid HIV testing,
which could result in overestimates of the acceptability
of HCV testing. We note, however, that HIV testing in
the UFO Study is voluntary and not part of routine
research testing. Since we have not measured the types
of HIV testing that participants have had we cannot
assess the effect of this potential exposure.
Through its accessibility in non-medical settings by lay-
workers, by not initially requiring phlebotomy or accessible
veins, and by providing immediate results, rapid testing
offers an important opportunity to enhance prevention
programs, and streamline access to care and treatment,
adding a critical new dimension to preventing and treating
HCV among vulnerable populations. Preference and ac-
ceptability should be assessed among those not already
being tested, in real-world settings and at other commu-
nity settings, such as substance abuse treatment centers,
drop-in services, and needle exchange programs.
Conclusion
Rapid anti-HCV antibody testing is likely to be a preferred
and accepted method of testing among young adult PWID
and has the potential to improve testing rates, enhance
prevention programs, and increase access to care. Further
study among other PWID groups and at other locations,
especially in non-urban areas is needed.
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